

**NEWS RELEASE** 

March 26, 2019

# EN Otsuka Pharmaceutical obtains marketing approval of ENORAS® Liquid for Enteral Use (for feeding tube and oral administration)

EN Otsuka Pharmaceutical Co., Ltd. (Head Office: Hanamaki, Iwate, Japan; President and Representative Director: Satoshi Muneyuki) has obtained the marketing approval of "ENORAS® Liquid for Enteral Use (ethical pharmaceutical for feeding tube and oral administration)" on March 26, 2019.

The product is a concentrated (1.6 kcal/mL) polymeric enteric nutrition formula based on the latest nutritional information to efficiently provide nutrients and energy in a small amount. Administration of 300 kcal per pouch is designed to meet approximately a third of the recommended daily amount of vitamins and trace elements specified in Dietary Reference Intakes for Japanese (2015). It also contains carnitine<sup>1</sup> and choline.<sup>2</sup>

As the effectiveness of ONS<sup>3</sup> as well as tube feeding has been shown in various situations recently, the oral intake is considered to be recommended more. The product is available in two flavors, yogurt and apple, so that patients can select and use according to their taste, and also considers the improvement of medication adherence.<sup>4</sup> The container is an aluminum pouch which is light and easy to discard.

The nutritional management using enteral nutrition formulas often lasts for a long time, and formulas with a small amount, high nutritional value, good flavor, and superior convenience are anticipated. We believe that this product will contribute to improving QOL of patients. EN Otsuka Pharmaceutical and Otsuka Pharmaceutical Factory which assumes responsibility for providing information aim to be the best partners of patients and healthcare professionals in the field of clinical nutrition by continuing to provide information and products which are useful for the adequate nutritional management

Based on the corporate philosophy of "Otsuka-people creating new products for better health worldwide," the Otsuka Group is dedicated to contributing to the health of people around the world.

<sup>&</sup>lt;sup>1</sup> Carnitine: A micronutrient which plays an important role in production of energy by lipid.

<sup>&</sup>lt;sup>2</sup> Choline: A micronutrient essential for constituting and repairing cell membranes and nervous tissues.

<sup>&</sup>lt;sup>3</sup> ONS (oral nutritional supplements): Intake of a small amount of enteral nutrition formula in addition to daily meal when the intake of meal is insufficient due to some diseases.

<sup>&</sup>lt;sup>4</sup> Medication adherence: Appropriate and correct intake of drugs by patients based on the correct understanding of the meanings and effectiveness of medication without discontinuation of intake by inappropriate judgment by themselves.

### Product Information

Brand Name	ENORAS® Liquid for Enteral Use		
Regulatory	Enteral nutrition (drug)		
Classification			
Packaging	<section-header><complex-block></complex-block></section-header>		
Indications	ENORAS Liquid for Enteral Use is indicated for nutritional support in		
	postoperative patients. It is specifically intended for tube feeding in patients in		
	whom oral nutrition is inadequate or not possible for a prolonged period.		
Dosage and	The standard adult dose of ENORAS Liquid for Enteral Use is 562.5–937.5 mL		
Administration	(900–1,500 kcal) per day, administered via tube feeding or orally. For tube		
	feeding, ENORAS Liquid for Enteral Use is administered to the patient		
	continuously or divided into several times a day with a rate of 50–400 mL/hr.		
	For oral intake, ENORAS Liquid for Enteral Use is administered once or divided		
	into several times a day. The dosage and administration time should be adjusted		
	according to the patient's age, weight, and clinical condition.		
Storage	Store at room temperature.		
Expiration Date	12 months after the date of manufacture (indicated on the pouch)		
Date of Marketing	March 26, 2019		
Approval			
Price	To be decided		
Manufactured and	EN Otsuka Pharmaceutical Co., Ltd.		
Distributed by			
Comarketed by	Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc.		

## Company Profile

#### EN Otsuka Pharmaceutical Co., Ltd.

Established	:	March 26, 2002
Capital	:	1.51 billion yen
Representative	:	Satoshi Muneyuki, President and Representative Director
Head Office	:	4-3-5 Nimaibashi, Hanamaki City, Iwate Prefecture 025-0312, Japan
Employees	:	347 (as of December 31, 2018)
Business	:	Research & development, manufacturing, sales, and the export/import of
Description		enteral nutrients, foods for medical use, foods for the elderly, disease-specific
		foods
URL	:	https://www.enotsuka.co.jp/en/

#### Otsuka Pharmaceutical Factory, Inc.

Established	:	October 7, 1969 (founded September 1, 1921)
Capital	:	80 million yen
Representative	:	Shinichi Ogasawara, President and Representative Director
Head Office	:	115 Kuguhara, Tateiwa, Muya-cho, Naruto, Tokushima 772-8601, Japan
Employees	:	2,266 (as of December 31, 2018)
Business	:	Manufacture, sale, import and export of clinical nutrition products and other
Description		pharmaceutical products, medical devices, functional foods, etc.
URL	:	https://www.otsukakj.jp/en/